Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients
- Metabolic and Rheumatology Units, Department of Medicine, University of Vermont Burlington, Vermont, and the Division of Endocrinology, Department of Medicine, University of Indiana School of Medicine Indianapolis, Indiana
- Address correspondence and reprint requests to Dr. David C. Robbins, The Metabolic Unit, Department of Medicine, Given C-352, University of Vermont, Burlington, VT 05405.
A covalent aggregate twice the size of insulin accounts for ∼28% of total circulating insulin immunoreactivity in type I diabetic patients. These aggregates are probably covalent dimers of insulin and should contain unique epitopes distinct from the parent molecule. Therapeutic insulin contains a similar material and is the source of the circulating aggregate. Anti-aggregate antibodies were detected by binding-inhibition techniques in 9 of 29 long-term diabetic patients. These antibodies were directed against structures distinct from those of the parent molecule insulin monomer. All antibody-positive patients were men whose blood also contained antibodies to insulin monomer. We conclude that the blood of ∼30% of insulin-using diabetic patients contains antibodies directed against epitopes unique to the insulin aggregates. Because insulin monomer and aggregates probably share a common primary amino acid sequence, the anti-aggregate antibodies are probably directed against conformational determinants. Further work is needed to determine whether such aggregates promote or accentuate the development of anti-insulin antibodies in certain genetically predisposed individuals.
- Received September 26, 1986.
- Revision received January 27, 1987.
- Accepted January 27, 1987.
- Copyright © 1987 by the American Diabetes Association